- Home
- LIQT vs CANF Comparison
LIQT vs CANF Comparison
Compare LIQT & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIQT
- CANF
- Stock Information
- Founded
- LIQT 2004
- CANF 1994
- Country
- LIQT Denmark
- CANF Israel
- Employees
- LIQT N/A
- CANF N/A
- Industry
- LIQT Industrial Machinery/Components
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- LIQT Technology
- CANF Health Care
- Exchange
- LIQT Nasdaq
- CANF Nasdaq
- Market Cap
- LIQT 16.1M
- CANF 13.5M
- IPO Year
- LIQT N/A
- CANF N/A
- Fundamental
- Price
- LIQT $1.90
- CANF $0.70
- Analyst Decision
- LIQT Strong Buy
- CANF Strong Buy
- Analyst Count
- LIQT 2
- CANF 2
- Target Price
- LIQT $4.80
- CANF $14.00
- AVG Volume (30 Days)
- LIQT 15.0K
- CANF 330.4K
- Earning Date
- LIQT 08-13-2025
- CANF 08-29-2025
- Dividend Yield
- LIQT N/A
- CANF N/A
- EPS Growth
- LIQT N/A
- CANF N/A
- EPS
- LIQT N/A
- CANF N/A
- Revenue
- LIQT $14,986,815.00
- CANF $674,000.00
- Revenue This Year
- LIQT $36.89
- CANF $461.72
- Revenue Next Year
- LIQT $16.33
- CANF N/A
- P/E Ratio
- LIQT N/A
- CANF N/A
- Revenue Growth
- LIQT N/A
- CANF N/A
- 52 Week Low
- LIQT $1.34
- CANF $0.63
- 52 Week High
- LIQT $3.20
- CANF $3.12
- Technical
- Relative Strength Index (RSI)
- LIQT 45.88
- CANF 22.87
- Support Level
- LIQT $1.94
- CANF $0.68
- Resistance Level
- LIQT $2.25
- CANF $1.05
- Average True Range (ATR)
- LIQT 0.23
- CANF 0.05
- MACD
- LIQT -0.05
- CANF -0.01
- Stochastic Oscillator
- LIQT 0.00
- CANF 15.83
About LIQT LiqTech International Inc.
LiqTech International Inc is a clean technology company which provides technology for gas and liquid purification by manufacturing ceramic silicon carbide filters. The company is engaged in three businesses that are diesel particulate filters (DPF) for the control of soot from diesel engines, turnkey ceramic membranes systems, and complete water treatment plants. The company's product portfolio consists of ceramic silicon membranes for liquid filtration, diesel particulate filters, and kiln furniture. Its operating segment includes Water, Ceramics, and Plastics.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).